Basic Information
| RNALocate ID: | RLID:11001434 |
| RNA Symbol: | hsa-miR-182-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-182-5p |
| RNA ID: | miRBase:MIMAT0000259 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001634 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001635 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001636 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001637 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
| RLID:01001638 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11001426 | Exosome | Pooled sera | 27278097 |
| RLID:11001427 | Exosome | Bronchoalveolar lavage fluid|Pooled sera | 27278097 |
| RLID:11001428 | Exosome | Human milk | 28688106 |
| RLID:11001429 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11001430 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11001431 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001432 | Exosome | Breast milk | 22211110 |
| RLID:11001433 | Exosome | Brain tissue | 23382797 |
| RLID:11001435 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11001436 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001437 | Microvesicle | Serum | 24797360 |
| RLID-D:11000052 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Tongue tissue | |
| RLID-D:11000321 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-182-5p | Oral squamous cell carcinoma | MNDR-E-MI-20345 |
| MNDR | hsa-miR-182-5p | Large cell neuroendocrine cancer | MNDR-E-MI-20346 |
| MNDR | hsa-miR-182-5p | Medulloblastoma | MNDR-E-MI-20347 |
| MNDR | hsa-miR-182-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-20348 |
| MNDR | hsa-miR-182-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-20349 |
| MNDR | hsa-miR-182-5p | Ovarian clear cell carcinoma | MNDR-E-MI-20350 |
| MNDR | hsa-miR-182-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-20351 |
| MNDR | hsa-miR-182-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-20352 |
| MNDR | hsa-miR-182-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-20353 |
| MNDR | hsa-miR-182-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-20354 |
| MNDR | hsa-miR-182-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-20355 |
| MNDR | hsa-miR-182-5p | Her2-receptor positive breast cancer | MNDR-E-MI-20356 |
| MNDR | hsa-miR-182-5p | Triple negative breast cancer | MNDR-E-MI-20357 |
| MNDR | hsa-miR-182-5p | Breast cancer luminal | MNDR-E-MI-20358 |
| MNDR | hsa-miR-182-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-20359 |
| MNDR | hsa-miR-182-5p | Hearing loss central | MNDR-E-MI-20360 |
| MNDR | hsa-miR-182-5p | Sensorineural hearing loss | MNDR-E-MI-20361 |
| MNDR | hsa-miR-182-5p | Small intestine cancer | MNDR-E-MI-20362 |
| MNDR | hsa-miR-182-5p | Prostate cancer | MNDR-E-MI-20363 |
| MNDR | hsa-miR-182-5p | Gastric cancer | MNDR-E-MI-20364 |
| MNDR | hsa-miR-182-5p | Gastric lymphoma | MNDR-E-MI-20365 |
| MNDR | hsa-miR-182-5p | Alzheimer disease | MNDR-E-MI-20366 |
| MNDR | hsa-miR-182-5p | Bladder cancer | MNDR-E-MI-20367 |
| MNDR | hsa-miR-182-5p | Head and neck cancer | MNDR-E-MI-20368 |
| MNDR | hsa-miR-182-5p | Ataxia telangiectasia | MNDR-E-MI-20369 |
| MNDR | hsa-miR-182-5p | Cardiovascular disease | MNDR-E-MI-20370 |
| MNDR | hsa-miR-182-5p | Lung cancer | MNDR-E-MI-20371 |
| MNDR | hsa-miR-182-5p | Down syndrome | MNDR-E-MI-20372 |
| MNDR | hsa-miR-182-5p | Parkinson disease | MNDR-E-MI-20373 |
| MNDR | hsa-miR-182-5p | Basal-like breast cancer | MNDR-E-MI-20374 |
| MNDR | hsa-miR-182-5p | Neuroendocrine neoplasia | MNDR-E-MI-20375 |
| MNDR | hsa-miR-182-5p | Thyroid cancer | MNDR-E-MI-20376 |
| MNDR | hsa-miR-182-5p | Pituitary neoplasms | MNDR-E-MI-20377 |
| MNDR | hsa-miR-182-5p | Pancreatic cancer | MNDR-E-MI-20378 |
| MNDR | hsa-miR-182-5p | Melanoma | MNDR-E-MI-20379 |
| MNDR | hsa-miR-182-5p | Rectum adenocarcinoma | MNDR-E-MI-20380 |
| MNDR | hsa-miR-182-5p | Nephroblastoma | MNDR-E-MI-20381 |
| MNDR | hsa-miR-182-5p | Colon cancer | MNDR-E-MI-20382 |
| MNDR | hsa-miR-182-5p | Colon adenocarcinoma | MNDR-E-MI-20383 |
| MNDR | hsa-miR-182-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-20384 |
| MNDR | hsa-miR-182-5p | Familial ovarian cancer | MNDR-E-MI-20385 |
| MNDR | hsa-miR-182-5p | Hereditary spastic paraplegia | MNDR-E-MI-20386 |
| MNDR | hsa-miR-182-5p | Prostate adenocarcinoma | MNDR-E-MI-20387 |
| MNDR | hsa-miR-182-5p | Kidney cancer | MNDR-E-MI-20388 |
| MNDR | hsa-miR-182-5p | Adenocarcinoma | MNDR-E-MI-20389 |
| MNDR | hsa-miR-182-5p | Carcinoma ductal breast | MNDR-E-MI-20390 |
| MNDR | hsa-miR-182-5p | Invasive ductal carcinoma | MNDR-E-MI-20391 |
| MNDR | hsa-miR-182-5p | Glioblastoma | MNDR-E-MI-20392 |
| MNDR | hsa-miR-182-5p | Astrocytoma | MNDR-E-MI-20393 |
| MNDR | hsa-miR-182-5p | Glioma | MNDR-E-MI-20394 |
| MNDR | hsa-miR-182-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-20395 |
| MNDR | hsa-miR-182-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-20396 |
| MNDR | hsa-miR-182-5p | Epilepsy temporal lobe | MNDR-E-MI-20397 |
| MNDR | hsa-miR-182-5p | Osteosarcoma | MNDR-E-MI-20398 |
| MNDR | hsa-miR-182-5p | Liposarcoma | MNDR-E-MI-20399 |
| MNDR | hsa-miR-182-5p | Breast carcinoma | MNDR-E-MI-20400 |
| MNDR | hsa-miR-182-5p | Uterine cancer | MNDR-E-MI-20401 |
| MNDR | hsa-miR-182-5p | Gastric adenocarcinoma | MNDR-E-MI-20402 |
| MNDR | hsa-miR-182-5p | Cervical squamous cell carcinoma | MNDR-E-MI-20403 |
| MNDR | hsa-miR-182-5p | Pituitary adenoma | MNDR-E-MI-20404 |
| MNDR | hsa-miR-182-5p | Lung squamous cell carcinoma | MNDR-E-MI-20405 |
| MNDR | hsa-miR-182-5p | Lung adenocarcinoma | MNDR-E-MI-20406 |
| MNDR | hsa-miR-182-5p | Thyroid carcinoma | MNDR-E-MI-20407 |
| MNDR | hsa-miR-182-5p | Ovarian carcinoma | MNDR-E-MI-20408 |
| MNDR | hsa-miR-182-5p | Bladder urothelial carcinoma | MNDR-E-MI-20409 |
| MNDR | hsa-miR-182-5p | Pancreatic adenocarcinoma | MNDR-E-MI-20410 |
| MNDR | hsa-miR-182-5p | Carcinoma renal cell | MNDR-E-MI-20411 |
| MNDR | hsa-miR-182-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-20412 |
| MNDR | hsa-miR-182-5p | Chromophobe renal cell carcinoma | MNDR-E-MI-20413 |
| MNDR | hsa-miR-182-5p | Large cell carcinoma | MNDR-E-MI-20414 |
| MNDR | hsa-miR-182-5p | Cholangiocarcinoma | MNDR-E-MI-20415 |
| MNDR | hsa-miR-182-5p | Esophageal cancer | MNDR-E-MI-20416 |
| MNDR | hsa-miR-182-5p | Oncocytoma | MNDR-E-MI-20417 |
| MNDR | hsa-miR-182-5p | Lung small cell carcinoma | MNDR-E-MI-20418 |
| MNDR | hsa-miR-182-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-20419 |
| MNDR | hsa-miR-182-5p | Heart failure | MNDR-E-MI-20420 |
| MNDR | hsa-miR-182-5p | Breast invasive carcinoma | MNDR-E-MI-20421 |
| MNDR | hsa-miR-182-5p | Hepatocellular carcinoma | MNDR-E-MI-20422 |
| MNDR | hsa-miR-182-5p | Familiar ovarian carcinoma | MNDR-E-MI-20423 |
| MNDR | hsa-miR-182-5p | B-cell lymphoma | MNDR-E-MI-20424 |
| MNDR | hsa-miR-182-5p | Rheumatoid arthritis | MNDR-E-MI-20425 |
| MNDR | hsa-miR-182-5p | T-cell leukemia | MNDR-E-MI-20426 |
| MNDR | hsa-miR-182-5p | Retinoblastoma | MNDR-E-MI-20427 |
| MNDR | hsa-miR-182-5p | Hodgkin lymphoma | MNDR-E-MI-20428 |
| MNDR | hsa-miR-182-5p | Burkitt lymphoma | MNDR-E-MI-20429 |
| MNDR | hsa-miR-182-5p | Crohn disease | MNDR-E-MI-20430 |
| MNDR | hsa-miR-182-5p | Neuromyelitis optica | MNDR-E-MI-20431 |
| MNDR | hsa-miR-182-5p | Acute myelocytic leukemia | MNDR-E-MI-20432 |
| MNDR | hsa-miR-182-5p | Colorectal cancer | MNDR-E-MI-20433 |
| MNDR | hsa-miR-182-5p | Multiple myeloma | MNDR-E-MI-20434 |
| MNDR | hsa-miR-182-5p | Acute lymphocytic leukemia | MNDR-E-MI-20435 |
| MNDR | hsa-miR-182-5p | Ovarian epithelial cancer | MNDR-E-MI-20436 |
| MNDR | hsa-miR-182-5p | Uterine cervical neoplasms | MNDR-E-MI-20437 |
| MNDR | hsa-miR-182-5p | Ependymoma | MNDR-E-MI-20438 |
| MNDR | hsa-miR-182-5p | Lung | MNDR-E-MI-20439 |
| MNDR | hsa-miR-182-5p | Prostatic neoplasms | MNDR-E-MI-20440 |
| MNDR | hsa-miR-182-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-20441 |
| MNDR | hsa-miR-182-5p | Stroke lacunar | MNDR-E-MI-20442 |
| MNDR | hsa-miR-182-5p | Breast cancer her3+ negative | MNDR-E-MI-20443 |
| MNDR | hsa-miR-182-5p | Duke A | MNDR-E-MI-20444 |
| MNDR | hsa-miR-182-5p | Low grade dysplastic nodule | MNDR-E-MI-20445 |
| MNDR | hsa-miR-182-5p | Non-sonic hedgehog-medulloblastoma | MNDR-E-MI-20446 |
| MNDR | hsa-miR-182-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-20447 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAMTS9-AS2 | Homo sapiens | RR00042742 |
TOP